Kornimate/medical-research-clean huggingface dataset:
good schools study

Conditions: Physical Violence; Educational Achievement; Mental Health; Sexual Violence; Violence Against Children

Summary: the purpose of this study is to determine whether use of the good schools toolkit is effective in reducing violence against children in primary schools.

violence against children has profound effects on both children's health and their ability to do well at school. fear, anxiety and injuries caused by violence may play a large role in both children's absenteeism and low educational achievement, and there is increasing interest from large bilateral donors in investigating this link in low income countries. the good school toolkit has been developed and refined for 6 years in uganda by raising voices. the toolkit takes a systemic approach, involving an entire school in a process of change to reduce violence and improve teaching techniques. the toolkit draws on the transtheoretical model and incorporates standard behaviour change techniques such as setting a goal and making an action plan, which are effective in modifying behaviour. this study aims to determine whether use of the good school toolkit reduces children's experience of violence by school staff. the investigators will also examine the effects of the toolkit on children's educational outcomes, mental health and well-being. the investigators will conduct a cluster randomised controlled trial in 40 primary schools in luwero district, uganda. more than 3500 children in primary 5, 6 and 7 will be surveyed (aged about 11-16 years). half of the schools will receive the toolkit, and other half will be put on a waiting list to receive the toolkit at the end of the study. the results from this evaluation will be used to brief policy-makers within the ministry of education and sports involved in developing country-wide policy and practice around violence against children in schools.

Eligibility criteria:
1. inclusion criteria: * schools * in luwero district, uganda * more than 40 students registered in primary 5 * participants * registered as a primary 5, 6 or 7 pupil * any school staff member 2. exclusion criteria: * schools -- existing program related to prevention of violence against children or school governance * participants -- not able to understand consent and study procedures

Keywords: corporal punishment violence education depression anxiety conduct disorder
laser efficiency on metabolic parameters

Conditions: Metabolic Syndrome

Summary: non-invasive laser therapy is laser blood irradiation improves many metabolic parameters. so, this study aims to assess the impact of non-invasive laser therapy on lipid metabolism and renal out comes

the metabolic syndrome is a constellation of interrelated metabolic risk factors especially central obesity, dyslipidemia, hyperglycemia, which all affect worse their kidney function, and all of this causing mortality. this time line requires a quick procedure that will enable us to implement safe and non-invasive therapeutic instruments adjacent therapy for metabolic syndrome cases.

Eligibility criteria:
inclusion criteria: * the patients have metabolic syndrome, started more than one year ago. * bmi ranged 30- 35kg/m2. * they are on medical therapy for more than one year. * clinically stable. exclusion criteria: * taking specific drugs uncontrolled diseases * cardiovascular instability * sever e autonomic neuropathy * infection wound, * burn, allergy or another external injury * hypothyroidism * hemorrhagic disorders * history of cancer * pregnant women, * mental illness as schizophrenia or dementia.
study to evaluate the efficacy and safety of combination aliskiren/amlodipine in patients not adequately responding to aliskiren alone

Conditions: Hypertension

Summary: this study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone


Eligibility criteria:
inclusion criteria: * newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to visit 1 must have a mean sitting diastolic blood pressure (msdbp) ≥ 95 mmhg and \< 110 mmhg at visits 1 and 2 * patients who have been treated for hypertension within the 4 weeks prior to - visit 1 must have a msdbp ≥ 90 mmhg and \< 110 mmhg at visit 2 * all patients must have a msdbp ≥ 90 mmhg and \< 110 mmhg at visit 4 exclusion criteria: * severe hypertension * pregnant or nursing (lactating) women * women of child-bearing potential * previous or current diagnosis of heart failure new york heart association (nyha class ii-iv) * serum potassium ≥ 5.3 meq/l (mmol/l) at visit 1 * uncontrolled type 1 or type 2 diabetes mellitus * hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures * history of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (tia), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention other protocol-defined inclusion/exclusion criteria may apply.

Keywords: aliskiren, amlodipine, non-responder to aliskiren
biological risk factors for onset of binge eating and compensatory behaviors

Conditions: Eating Disorder

Summary: the purpose of this proposed project is to test whether several biological factors (such as elevated brain reward region and attention region response to high-calorie foods, weaker inhibitory region response to high-calorie foods, habitual caloric deprivation, and elevated limbic region responsivity) increase the risk of problematic eating (bingeing and purging) in female adolescents.

participants will be adolescent girls aged 13-16, some of whom will have parental history of eating pathology. participants will be recruited from the general population but their age, gender, and the presence of parental lifetime eating pathology will create a high-risk sample. the goals of the proposed project are to (1) conduct a prospective high-risk study to test whether proposed biological risk factors predict the future onset of core ed symptoms (e.g., binge eating, compensatory behaviors); (2) test hypotheses regarding how these biological risk factors and established self-report ed risk factors may work together to predict ed behavior onset; (3) examine if certain biological factors account for the effects of certain established self-reported ed risk factors (e.g., elevated brain response to thin models accounts for the effect of questionnaire-measured thin-ideal internalization). the participants will complete a baseline assessment and then follow-ups assessments over a span of three years. in addition, participants will complete one fmri scan after the first assessment. during the covid-19 shelter-at-home order, the investigators will not measure in person only outcomes including fmri scans, height and weight measurement for bmi calculation nor iat computer paradigms for all participants that have assessments due during this order.

Eligibility criteria:
* inclusion criteria: * female * aged 13-16 years * exclusion criteria: * adolescents who report functional magnetic resonance imaging (fmri) contraindications * current diagnostic and statistical manual of mental disorders 5 (dsm-5) substance abuse disorder, eating disorder (ed), conduct disorder, attention deficit hyperactivity disorder (adhd), or bipolar disorder * weekly or greater use of psychoactive drugs (e.g., analgesics, cocaine, marijuana) * serious medical complications (e.g., cancer, diabetes) * history of head injury * relevant food allergies * bmi \> 35

Keywords: fmri eating disorder adolescent
geisinger education intervention study in obesity protocol

Conditions: Obesity

Summary: overweight and obesity has become an epidemic which warrants more aggressive treatment. however, few primary care physicians (pcps) address this issue or do not possess adequate education regarding treatment modalities such as nutrition counseling or bariatric surgery. the primary goal of this study will be to determine whether the referrals for weight management can be influenced through obesity education.

evaluation of educational interventions focusing on the treatment of obesity will include in person cme sessions, interactive game/virtual patient computer software and two 30 minute dvd/web-based cme opportunities that the physicians can review at their leisure. these educational interventions were not completed as part of this research. a control group will be comprised of those healthcare professionals who did not complete the cme survey. completion of the post education survey would be completed even if there was no study. the reward given to pcp's (free enrollment in cme session and either lab coat or $40 cme credit) was given for clinical purposes only and not for research. the study consists of the collection of pcp referral rates prior to the educational opportunity and then after the cme looking for a change to referral rates. in june of 2009, an obesity educational intervention summit was attended by pcps. this research seeks approval to perform data pulls consisting of referrals from their practice to the gi/nutrition clinic for potential bariatric surgery evaluation. the information to be collected regarding the primary care providers' referral rates will be collected by a cdis data pull by a data broker. the biostatistician will link survey responses to referral patterns and education type and will be true, only individual to have access to direct identifiers and in turn will provide pi and study team with de-identified summary data.

Eligibility criteria:
inclusion criteria: geisinger general internal and family medicine pcps (include physician, physical assistants and crnp): * pcp must be active between may 2008 - may 2009 * average patient age between 30-60 (no individual patients will be identified using personal identification) * minimum of 100 patients assigned to pc exclusion criteria: * pcps from clinics/departments other than general internal medicine or family medicine will be excluded from the analysis

Keywords: obestiy over weight referral patterns continuing medical education
re-engagement at discharge 2

Conditions: HIV/AIDS; Hospitalization; Transitions of Care; Opportunistic Infections

Summary: early post-discharge mortality is high among zambians living with hiv admitted to the hospital. this may be due to missed opportunities in post-discharge care, such as inadequate follow-up and treatment. in this study the investigators will develop and pilot a new approach to post-discharge hiv care to improve care coordination and treatment adherence.

many people living with hiv (plhiv) have poor outcomes following hospitalization, including high mortality, readmission, and gaps in hiv care engagement. this is likely multi-factorial and not all etiologies may be modifiable. while high mortality may due to incurable cancer, the majority of deaths in plhiv are thought to be caused by infectious diseases for which treatments exist. however, succumbing to these life-threatening infections after discharge may be due to poor understanding of discharge instructions, lack of post hospital care, and poor understanding of required follow up. psychosocial support also plays a role in the mental and physical health of these sick patients. in recharge 1, the investigators gathered formative data and identified at least three major factors that undermine hiv clinical outcomes after hospital discharge. first, there are gaps in continuity of care between the discharging facility and outpatient. second, support from family is often suboptimal due to lack of understanding on the cause of illness, lack of hiv status disclosure, and the cost of care. third, hiv comorbidities may underpin or complicate the immediate reason for discharge or the post-discharge engagement in care. these data were disseminated to local experts in zambia including from the ministry of health and used to create a new care model for post-discharge hiv care. the care model draws from other successful programs in zambia. in recharge 2 the investigators now propose to pilot the program and assess feasibility, acceptability, and potential for clinical impact.

Eligibility criteria:
inclusion criteria: * age 18+ years * hiv-positive * hospitalized for at least 1 night at study site * clinically stable and expected to be discharged according to their clinician * objective evidence of suboptimal hiv outcome, defined as hiv viral load above the lower limit of the assay or t-cell cluster of differentiation 4 count \<=200. exclusion criteria: * unable to provide informed consent * no phone * planning to reside outside of lusaka urban district after discharge
increasing engagement in ptsd treatment through patient education and patient choice

Conditions: Posttraumatic Stress Disorder (PTSD)

Summary: the purpose of this program is to compare two different methods of matching a veteran to a ptsd treatment.

posttraumatic stress disorder (ptsd) is a serious disorder that affects many veterans who have had a traumatic experience. the va offers several different types of treatment for ptsd. we are researching different ways to match a veteran to a type of treatment. participants in this study will will be randomly assigned to either a 40-minute session in which they will learn about ptsd treatments and select a preferred treatment or to a 40-minute assessment interview. those participants assigned to the assessment interview will have the opportunity to work with their trauma recovery program provider to determine a plan for their ptsd treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of combat-related ptsd * newly enrolled in trauma recovery program (trp) at the michael e. debakey va medical center * trp provider approval exclusion criteria: * previous participation in trp treatment for ptsd

Keywords: posttraumatic stress disorder ptsd treatment decision making veterans
clinical trial to evaluate the use of platelet rich plasma in front hyaluronic acid in coxarthrosis

Conditions: Coxarthrosis

Summary: to evaluate the efficacy and safety of platelet rich plasma (prp) in patients with coxarthrosis who don´t respond to treatment with nsaids, compared to treatment with hyaluronic acid (hylan g-f 20).


Eligibility criteria:
inclusion criteria: * patients\> 30 years. * patients who voluntarily express their intention to participate by informed consent. * diagnosis of coxarthrosis who have failed conservative treatments for 6 months * women of childbearing potential must have a negative pregnancy test during screening and must agree to use adequate contraception (or two contraceptive methods, of which one is barrier) while participating in the trial. exclusion criteria: * treatment with infiltrations 3 months prior to the study * prior treatment with nsaids 24h prior to extraction * pre-surgical treatment of hip affects * diabetics * severe liver or kidney disease at the time of extraction * thrombocytopenia (\<100,000 platelets / ml) at baseline * anemia (hb 9 \<mg / dl) at baseline * hyaluronic acid allergy * history crystal arthropathy, inflammatory arthritis or neuropathic arthropathy. * acetabular protrusions * history of infectious arthritis * excessive deformity (acetabular dysplasia, perthes)

Keywords: platelet-rich plasma (prp) hyaluronic acid (hylan g-f 20). nsaids womac
platelet enriched plasma for treatment of interstitial cystitis

Conditions: Interstitial Cystitis; Bladder Pain Syndrome; Platelet Enriched Plasma

Summary: a prospective randomized trial will be conducted aiming at evaluation the efficacy and safety of platelet enriched plasma for management of bladder pain syndrome .


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of interstitial cystitis/ bladder painful syndrome for more than 3 months will be enrolled exclusion criteria: * patients with anemia, blood disorders, history of pelvic irradiation, pelvic malignancy, and active urinary tract infection unless treated, vesical stone, gynecological disorders e.g. uterine fibroid and neurological disorders will be excluded. patients less than 18 years old will not be allowed to participate.
pain in carpal tunnel release wide-awake local anesthesia with no tourniquet vs local anesthesia with tourniquet

Conditions: Carpal Tunnel Syndrome

Summary: the aim of this study is to compare pain, satisfaction, and experience between patients who underwent carpal tunnel release with wide-awake local anesthesia no tourniquet technique and local anesthesia with a tourniquet.

the surgical pathology of the hand has grown exponentially. in most cases, the resolution is performed in outpatients with short surgical times. given the increased demand for this type of surgery, surgeons have sought different variables to reduce the costs and human resources. thus, the wide-awake local anesthesia no tourniquet procedure (walant). it deals with the non-need for anesthetic monitoring and with the regional use of anesthesia with epinephrine. its use avoids placing a pneumatic cuff on the arm owing to the vasoconstrictive action of epinephrine. however, the drug takes 25-30 minutes to achieve the maximum hemostatic effect, and adverse effects, such as distal necrosis, have been reported. therefore, the technique of local anesthesia without epinephrine with a tourniquet (la-t) is also used daily by hand surgeons. the use of a tourniquet, a pneumatic cuff, for less than 20 minutes has been associated with the same or lower pain profiles than the wide-awake local anesthesia no tourniquet without running the risk of adverse effects of epinephrine. the objective of this study is to compare and assess pain and patient experience after short-duration hand surgery using the walant and la-t techniques. the investigators hypothesized that both types of procedures had a similar level of satisfaction.

Eligibility criteria:
inclusion criteria: * carpal tunnel syndrome with surgical resolution * surgical procedures takes less than 30 minutes exclusion criteria: * lost follow-up
the evaluation of erector spinae plane block for the pain control of thoracic postherpetic neuralgia

Conditions: Thoracic Postherpetic Neuralgia

Summary: erector spinae plane block is new interfascial plane block, and can be applied to management of thoracic neuropathic pain syndromes. the target of needle is deeper(or anterior) to the erector spinae muscle. so it is more safe and simple technique than prior technique, thoracic paravertebral block. the aim of this study is the evaluation of erector spinae plane block comparison to prevertebra block.

this study is single-blind because it is not possible to blind the practitioner performing the injection. subjects were randomly assigned to the erector spinae plane block group (group e) and the thoracic paravertebral block group (group p) by a random random number table, and the possibilities for belonging to any group were all the same and can not be artificially controlled by researchers. before the procedure, a resident who does not know of this study records the patient's pain and paindetect. and on follow-up four weeks visits, pgic scale is checked. the erector spinae plane block or thoracic paravertebral block should be performed after receiving the informed consent of the patient. because of the large difference between the skilled and unskilled patients, the procedure in this study is performed by only one skilled practitioner.

Eligibility criteria:
inclusion criteria: 1. inclusion criteria were patients who had chest wall post herpetic neuralgia, with moderate and severe pain and received appropriate antiviral therapy. exclusion criteria: 1. patient refusal 2. patients who did not receive appropriate antiviral therapy 3. patients with mild pain 4. heavy skin eruption (no healthy area for needle entry) and infection at site of injection. 5. patients with history of renal, hepatic diseases, coagulopathy, diabetes 6. patients taking chemotherapy and/or radiotherapy 7. patients with history of steroid therapy 8. patients taking narcotic analgesics 9. patient who does not understand the study because of illiteracy or language problems. 10. abnormal findings in peripheral blood test (cbc, esr, crp, pt/aptt)

Keywords: thoracic paravertebral block erector spinae plane block thoracic postherpetic neuralgia
gemtuzumab ozogamicin+cytarabine vs idarubicin+cytarabine in elderly patients with aml.mylofrance 4

Conditions: Acute Myeloid Leukemia

Summary: purpose : the main objective of this study is to assess the efficacy and tolerance of the addition of repeated doses of low doses (3mg/m2) of gemtuzumab ozogamicin (go) in addition with standard doses of ara-c in previously untreated patients aged 60 to 80 years with de novo acute myeloblastic leukemia (aml) and non adverse cytogenetics. the main end point for efficacy is 2 years-event free survival. the secondary efficacy endpoints are cr/cri rates, cumulative incidence of relapse and overall survival. the secondary endpoints for safety are early death rate (before day 30 and 60), grade 3 to 5 adverse events and severe adverse events, cardiac toxicity and quality of life. additional secondary endpoints are treatment by covariate interactions with respect to biological characteristics present at diagnosis (cd33 positivity, cytogenetic, molecular abnormalities) or after treatment (minimal residual disease levels). this study is an exploratory study. patients will be allocated at inclusion with a 2/1 ratio either to receive treatment with go and cytarabine or idarubicin and cytarabine in a 3+7 regimen similar to the "backbone" alfa 1200 scheme used concurrently by the alfa group as treatment of aml patients aged \>60 years. primary objective. the primary objective is to assess the efficacy of two doses of gemtuzumab ozogamicin (go) during induction and one dose of go during first consolidation in combination with cytarabine in elderly patients with aml in the non adverse cytogenetics-risk group.


Eligibility criteria:
inclusion criteria: * patients with a morphologically proven diagnosis aml and both the following criteria: * age ≥ 60 years and \< 80 years. * not previously treated for their disease. * with favourable or intermediate-risk cytogenetics. (patients with urgent clinical need to begin treatment might be included before cytogenetic results, when necessary if they do not respond to hydroxyurea. patients might be included if the cytogenetic results are not expected in a time limit \< 5 days after aml diagnosis). * fit to receive intensive chemotherapy * cardiac function determined by radionucleide or echography within normal limits. * signed informed consent exclusion criteria: * m3-aml * presence of adverse cytogenetics (according to european leukemianet recommendation.) (17) defined as one of the following abnormalities: -5/5q-, -7, t(6;9), t(v;11q23) excluding t(9;11), inv(3)(q21;q26.2) or t(3;3)(q21;q26.2), complex karyotype (3+ abnormalities) * secondary aml following treatment with radiotherapy or chemotherapy. * aml following previously known myeloproliferative or myelodysplastic syndrome. * ecog performance status (ps) 0 to 3 * serum creatinin level \> or = 2.5n; ast and alt level \> or = 2.5n; total bilirubin level \> or = 2n

Keywords: aml untreated 60-80 years old favorable and intermediate karyotype